-
1
-
-
84892805731
-
Cancer statistics, 2014
-
Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
-
(2014)
CA Cancer J Clin
, vol.64
, pp. 9-29
-
-
Siegel, R.1
Ma, J.2
Zou, Z.3
Jemal, A.4
-
2
-
-
84894099296
-
The economic burden of skeletal-related events among elderly men with metastatic prostate cancer
-
Jayasekera J., Onukwugha E., Bikov K., Mullins C.D., Seal B., Hussain A. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer. PharmacoEconomics 2014, 32:173-191.
-
(2014)
PharmacoEconomics
, vol.32
, pp. 173-191
-
-
Jayasekera, J.1
Onukwugha, E.2
Bikov, K.3
Mullins, C.D.4
Seal, B.5
Hussain, A.6
-
3
-
-
84899482355
-
Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer
-
Yong C., Onukwugha E., Mullins C.D. Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer. Curr Opin Oncol 2014, 26:274-283.
-
(2014)
Curr Opin Oncol
, vol.26
, pp. 274-283
-
-
Yong, C.1
Onukwugha, E.2
Mullins, C.D.3
-
4
-
-
66149161780
-
Castration-resistant prostate cancer: locking up the molecular escape routes
-
Attar R.M., Takimoto C.H., Gottardis M.M. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 2009, 15:3251-3255.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3251-3255
-
-
Attar, R.M.1
Takimoto, C.H.2
Gottardis, M.M.3
-
5
-
-
60149089419
-
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nature clinical practice
-
Harris W.P., Mostaghel E.A., Nelson P.S., Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nature clinical practice. Urology 2009, 6:76-85.
-
(2009)
Urology
, vol.6
, pp. 76-85
-
-
Harris, W.P.1
Mostaghel, E.A.2
Nelson, P.S.3
Montgomery, B.4
-
6
-
-
79956345344
-
Screening for prostate cancer with PSA testing: current status and future directions
-
[63]
-
Croswell J.M., Kramer B.S., Crawford E.D. Screening for prostate cancer with PSA testing: current status and future directions. Oncology (Williston Park) 2011, 25:452-460. [63].
-
(2011)
Oncology (Williston Park)
, vol.25
, pp. 452-460
-
-
Croswell, J.M.1
Kramer, B.S.2
Crawford, E.D.3
-
7
-
-
84861847420
-
Prostate-cancer mortality after PSA screening
-
D'Amico A.V. Prostate-cancer mortality after PSA screening. N Engl J Med 2012, 366:2229.
-
(2012)
N Engl J Med
, vol.366
, pp. 2229
-
-
D'Amico, A.V.1
-
8
-
-
79960444176
-
Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?
-
Duffy M.J. Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?. Ann Clin Biochem 2011, 48:310-316.
-
(2011)
Ann Clin Biochem
, vol.48
, pp. 310-316
-
-
Duffy, M.J.1
-
9
-
-
84896466669
-
Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence
-
Hayes J.H., Barry M.J. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA 2014, 311:1143-1149.
-
(2014)
JAMA
, vol.311
, pp. 1143-1149
-
-
Hayes, J.H.1
Barry, M.J.2
-
10
-
-
84871908883
-
The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States
-
Howrey B.T., Kuo Y.F., Lin Y.L., Goodwin J.S. The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. J Gerontol A: Biol Med Sci 2013, 68:56-61.
-
(2013)
J Gerontol A: Biol Med Sci
, vol.68
, pp. 56-61
-
-
Howrey, B.T.1
Kuo, Y.F.2
Lin, Y.L.3
Goodwin, J.S.4
-
11
-
-
84898753498
-
Further evidence that prostate-specific antigen screening reduces prostate cancer mortality
-
Stampfer M.J., Jahn J.L., Gann P.H. Further evidence that prostate-specific antigen screening reduces prostate cancer mortality. J Natl Cancer Inst 2014, 106:dju026.
-
(2014)
J Natl Cancer Inst
, vol.106
-
-
Stampfer, M.J.1
Jahn, J.L.2
Gann, P.H.3
-
12
-
-
84905912396
-
A different method of evaluation of the ERSPC Trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality
-
Zappa M., Puliti D., Hugosson J., Schroder F.H., van Leeuwen P.J., Kranse R., et al. A different method of evaluation of the ERSPC Trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality. Eur Urol 2014, 66:401-403.
-
(2014)
Eur Urol
, vol.66
, pp. 401-403
-
-
Zappa, M.1
Puliti, D.2
Hugosson, J.3
Schroder, F.H.4
van Leeuwen, P.J.5
Kranse, R.6
-
13
-
-
84874543674
-
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases
-
Nilsson S., Franzen L., Parker C., Tyrrell C., Blom R., Tennvall J., et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer 2013, 11:20-26.
-
(2013)
Clin Genitourin Cancer
, vol.11
, pp. 20-26
-
-
Nilsson, S.1
Franzen, L.2
Parker, C.3
Tyrrell, C.4
Blom, R.5
Tennvall, J.6
-
14
-
-
0042854927
-
Peptide receptors as molecular targets for cancer diagnosis and therapy
-
Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003, 24:389-427.
-
(2003)
Endocr Rev
, vol.24
, pp. 389-427
-
-
Reubi, J.C.1
-
15
-
-
57349195981
-
Peptide-based probes for cancer imaging
-
Reubi J.C., Maecke H.R. Peptide-based probes for cancer imaging. J Nucl Med 2008, 49:1735-1738.
-
(2008)
J Nucl Med
, vol.49
, pp. 1735-1738
-
-
Reubi, J.C.1
Maecke, H.R.2
-
16
-
-
25144503630
-
-
APhA, American Pharmacists Association, Washington, D.C. 2nd ed.
-
Kowalsky R.J., Falen S.W., Kowalsky R.J. Radiopharmaceuticals in nuclear pharmacy and nuclear medicine 2004, APhA, American Pharmacists Association, Washington, D.C. 2nd ed.
-
(2004)
Radiopharmaceuticals in nuclear pharmacy and nuclear medicine
-
-
Kowalsky, R.J.1
Falen, S.W.2
Kowalsky, R.J.3
-
17
-
-
77956985437
-
64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model
-
64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model. Nucl Med Biol 2010, 37:751-761.
-
(2010)
Nucl Med Biol
, vol.37
, pp. 751-761
-
-
Lane, S.R.1
Nanda, P.2
Rold, T.L.3
Sieckman, G.L.4
Figueroa, S.D.5
Hoffman, T.J.6
-
18
-
-
34547176710
-
64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties
-
64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties. Bioconjug Chem 2007, 18:1110-1117.
-
(2007)
Bioconjug Chem
, vol.18
, pp. 1110-1117
-
-
Parry, J.J.1
Kelly, T.S.2
Andrews, R.3
Rogers, B.E.4
-
19
-
-
84876950056
-
Near-infrared fluorescence imaging of gastrin releasing peptide receptor targeting in prostate cancer lymph node metastases
-
Cai Q.Y., Yu P., Besch-Williford C., Smith C.J., Sieckman G.L., Hoffman T.J., et al. Near-infrared fluorescence imaging of gastrin releasing peptide receptor targeting in prostate cancer lymph node metastases. Prostate 2013, 73:842-854.
-
(2013)
Prostate
, vol.73
, pp. 842-854
-
-
Cai, Q.Y.1
Yu, P.2
Besch-Williford, C.3
Smith, C.J.4
Sieckman, G.L.5
Hoffman, T.J.6
-
21
-
-
67650726009
-
Structural assessment and biological evaluation of two N3S bombesin derivatives
-
Gourni E., Bouziotis P., Benaki D., Loudos G., Xanthopoulos S., Paravatou-Petsotas M., et al. Structural assessment and biological evaluation of two N3S bombesin derivatives. J Med Chem 2009, 52:4234-4246.
-
(2009)
J Med Chem
, vol.52
, pp. 4234-4246
-
-
Gourni, E.1
Bouziotis, P.2
Benaki, D.3
Loudos, G.4
Xanthopoulos, S.5
Paravatou-Petsotas, M.6
-
22
-
-
0033104343
-
Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation
-
Markwalder R., Reubi J.C. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999, 59:1152-1159.
-
(1999)
Cancer Res
, vol.59
, pp. 1152-1159
-
-
Markwalder, R.1
Reubi, J.C.2
-
23
-
-
12144279487
-
Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study
-
Nock B.A., Nikolopoulou A., Galanis A., Cordopatis P., Waser B., Reubi J.C., et al. Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem 2005, 48:100-110.
-
(2005)
J Med Chem
, vol.48
, pp. 100-110
-
-
Nock, B.A.1
Nikolopoulou, A.2
Galanis, A.3
Cordopatis, P.4
Waser, B.5
Reubi, J.C.6
-
24
-
-
84862577703
-
Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates
-
Patil V., Gada K., Panwar R., Varvarigou A., Majewski S., Weisenberger A., et al. Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates. Eur J Nucl Med Mol Imaging 2012, 39:824-839.
-
(2012)
Eur J Nucl Med Mol Imaging
, vol.39
, pp. 824-839
-
-
Patil, V.1
Gada, K.2
Panwar, R.3
Varvarigou, A.4
Majewski, S.5
Weisenberger, A.6
-
26
-
-
79958060431
-
Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts
-
Schroeder R.P., van Weerden W.M., Krenning E.P., Bangma C.H., Berndsen S., Grievink-de Ligt C.H., et al. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts. Eur J Nucl Med Mol Imaging 2011, 38:1257-1266.
-
(2011)
Eur J Nucl Med Mol Imaging
, vol.38
, pp. 1257-1266
-
-
Schroeder, R.P.1
van Weerden, W.M.2
Krenning, E.P.3
Bangma, C.H.4
Berndsen, S.5
Grievink-de Ligt, C.H.6
-
28
-
-
0043267475
-
Radiochemical investigations of gastrin-releasing peptide receptor-specific [(99m)Tc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where Dpr=2,3-diaminopropionic acid and X=H2O or P(CH2OH)3
-
Smith C.J., Sieckman G.L., Owen N.K., Hayes D.L., Mazuru D.G., Kannan R., et al. Radiochemical investigations of gastrin-releasing peptide receptor-specific [(99m)Tc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where Dpr=2,3-diaminopropionic acid and X=H2O or P(CH2OH)3. Cancer Res 2003, 63:4082-4088.
-
(2003)
Cancer Res
, vol.63
, pp. 4082-4088
-
-
Smith, C.J.1
Sieckman, G.L.2
Owen, N.K.3
Hayes, D.L.4
Mazuru, D.G.5
Kannan, R.6
-
29
-
-
2542506187
-
Gastrin-releasing peptide (GRP) analogues for cancer imaging
-
Varvarigou A., Bouziotis P., Zikos C., Scopinaro F., De Vincentis G. Gastrin-releasing peptide (GRP) analogues for cancer imaging. Cancer Biother Radiopharm 2004, 19:219-229.
-
(2004)
Cancer Biother Radiopharm
, vol.19
, pp. 219-229
-
-
Varvarigou, A.1
Bouziotis, P.2
Zikos, C.3
Scopinaro, F.4
De Vincentis, G.5
-
30
-
-
33646050623
-
64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma
-
64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol 2006, 33:371-380.
-
(2006)
Nucl Med Biol
, vol.33
, pp. 371-380
-
-
Yang, Y.S.1
Zhang, X.2
Xiong, Z.3
Chen, X.4
-
31
-
-
84878863911
-
An update of radiolabeled bombesin analogs for gastrin-releasing peptide receptor targeting
-
Yu Z., Ananias H.J., Carlucci G., Hoving H.D., Helfrich W., Dierckx R.A., et al. An update of radiolabeled bombesin analogs for gastrin-releasing peptide receptor targeting. Curr Pharm Des 2013, 19:3329-3341.
-
(2013)
Curr Pharm Des
, vol.19
, pp. 3329-3341
-
-
Yu, Z.1
Ananias, H.J.2
Carlucci, G.3
Hoving, H.D.4
Helfrich, W.5
Dierckx, R.A.6
-
32
-
-
83755170780
-
Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors
-
Abiraj K., Mansi R., Tamma M.L., Fani M., Forrer F., Nicolas G., et al. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med 2011, 52:1970-1978.
-
(2011)
J Nucl Med
, vol.52
, pp. 1970-1978
-
-
Abiraj, K.1
Mansi, R.2
Tamma, M.L.3
Fani, M.4
Forrer, F.5
Nicolas, G.6
-
33
-
-
0023637601
-
New perspectives in cell adhesion: RGD and integrins
-
Ruoslahti E., Pierschbacher M.D. New perspectives in cell adhesion: RGD and integrins. Science 1987, 238:491-497.
-
(1987)
Science
, vol.238
, pp. 491-497
-
-
Ruoslahti, E.1
Pierschbacher, M.D.2
-
34
-
-
0033119722
-
RGD-recognizing integrins mediate interactions of human prostate carcinoma cells with endothelial cells in vitro
-
Romanov V.I., Goligorsky M.S. RGD-recognizing integrins mediate interactions of human prostate carcinoma cells with endothelial cells in vitro. Prostate 1999, 39:108-118.
-
(1999)
Prostate
, vol.39
, pp. 108-118
-
-
Romanov, V.I.1
Goligorsky, M.S.2
-
35
-
-
84872019911
-
RGD-binding integrins in prostate cancer: expression patterns and therapeutic prospects against bone metastasis
-
Sutherland M., Gordon A., Shnyder S.D., Patterson L.H., Sheldrake H.M. RGD-binding integrins in prostate cancer: expression patterns and therapeutic prospects against bone metastasis. Cancers 2012, 4:1106-1145.
-
(2012)
Cancers
, vol.4
, pp. 1106-1145
-
-
Sutherland, M.1
Gordon, A.2
Shnyder, S.D.3
Patterson, L.H.4
Sheldrake, H.M.5
-
36
-
-
73349138610
-
177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression
-
177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression. J Nucl Med 2009, 50:2017-2024.
-
(2009)
J Nucl Med
, vol.50
, pp. 2017-2024
-
-
Maddalena, M.E.1
Fox, J.2
Chen, J.3
Feng, W.4
Cagnolini, A.5
Linder, K.E.6
-
37
-
-
65249138736
-
Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers
-
Shi J., Kim Y.S., Zhai S., Liu Z., Chen X., Liu S. Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. Bioconjug Chem 2009, 20:750-759.
-
(2009)
Bioconjug Chem
, vol.20
, pp. 750-759
-
-
Shi, J.1
Kim, Y.S.2
Zhai, S.3
Liu, Z.4
Chen, X.5
Liu, S.6
-
38
-
-
33750420717
-
Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging
-
Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharm 2006, 3:472-487.
-
(2006)
Mol Pharm
, vol.3
, pp. 472-487
-
-
Liu, S.1
-
39
-
-
67651122837
-
Ligands for mapping alphavbeta3-integrin expression in vivo
-
Schottelius M., Laufer B., Kessler H., Wester H.J. Ligands for mapping alphavbeta3-integrin expression in vivo. Acc Chem Res 2009, 42:969-980.
-
(2009)
Acc Chem Res
, vol.42
, pp. 969-980
-
-
Schottelius, M.1
Laufer, B.2
Kessler, H.3
Wester, H.J.4
-
40
-
-
0036930886
-
Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting
-
Janssen M., Oyen W.J., Massuger L.F., Frielink C., Dijkgraaf I., Edwards D.S., et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm 2002, 17:641-646.
-
(2002)
Cancer Biother Radiopharm
, vol.17
, pp. 641-646
-
-
Janssen, M.1
Oyen, W.J.2
Massuger, L.F.3
Frielink, C.4
Dijkgraaf, I.5
Edwards, D.S.6
-
42
-
-
27944457471
-
MicroPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide
-
Wu Y., Zhang X., Xiong Z., Cheng Z., Fisher D.R., Liu S., et al. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med 2005, 46:1707-1718.
-
(2005)
J Nucl Med
, vol.46
, pp. 1707-1718
-
-
Wu, Y.1
Zhang, X.2
Xiong, Z.3
Cheng, Z.4
Fisher, D.R.5
Liu, S.6
-
43
-
-
33845697526
-
Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide
-
Dijkgraaf I., Kruijtzer J.A., Frielink C., Corstens F.H., Oyen W.J., Liskamp R.M., et al. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. Int J Cancer 2007, 120:605-610.
-
(2007)
Int J Cancer
, vol.120
, pp. 605-610
-
-
Dijkgraaf, I.1
Kruijtzer, J.A.2
Frielink, C.3
Corstens, F.H.4
Oyen, W.J.5
Liskamp, R.M.6
-
44
-
-
34447336118
-
(64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression
-
Li Z.B., Cai W., Cao Q., Chen K., Wu Z., He L., et al. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med 2007, 48:1162-1171.
-
(2007)
J Nucl Med
, vol.48
, pp. 1162-1171
-
-
Li, Z.B.1
Cai, W.2
Cao, Q.3
Chen, K.4
Wu, Z.5
He, L.6
-
47
-
-
84859976754
-
(68)Ga-Labeling of RGD peptides and biodistribution
-
Blom E., Velikyan I., Estrada S., Hall H., Muhammad T., Ding C., et al. (68)Ga-Labeling of RGD peptides and biodistribution. Int J Clin Exp Med 2012, 5:165-172.
-
(2012)
Int J Clin Exp Med
, vol.5
, pp. 165-172
-
-
Blom, E.1
Velikyan, I.2
Estrada, S.3
Hall, H.4
Muhammad, T.5
Ding, C.6
-
50
-
-
84892992101
-
A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] alphavbeta3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors
-
Durkan K., Jiang Z., Rold T.L., Sieckman G.L., Hoffman T.J., Bandari R.P., et al. A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] alphavbeta3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors. Nucl Med Biol 2014, 41:133-139.
-
(2014)
Nucl Med Biol
, vol.41
, pp. 133-139
-
-
Durkan, K.1
Jiang, Z.2
Rold, T.L.3
Sieckman, G.L.4
Hoffman, T.J.5
Bandari, R.P.6
-
51
-
-
66149176919
-
(18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer
-
Liu Z., Yan Y., Liu S., Wang F., Chen X. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjug Chem 2009, 20:1016-1025.
-
(2009)
Bioconjug Chem
, vol.20
, pp. 1016-1025
-
-
Liu, Z.1
Yan, Y.2
Liu, S.3
Wang, F.4
Chen, X.5
-
52
-
-
67650093751
-
Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer
-
Liu Z., Li Z.B., Cao Q., Liu S., Wang F., Chen X. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer. J Nucl Med 2009, 50:1168-1177.
-
(2009)
J Nucl Med
, vol.50
, pp. 1168-1177
-
-
Liu, Z.1
Li, Z.B.2
Cao, Q.3
Liu, S.4
Wang, F.5
Chen, X.6
-
54
-
-
68949212307
-
(68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging
-
Liu Z., Niu G., Wang F., Chen X. (68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging 2009, 36:1483-1494.
-
(2009)
Eur J Nucl Med Mol Imaging
, vol.36
, pp. 1483-1494
-
-
Liu, Z.1
Niu, G.2
Wang, F.3
Chen, X.4
-
55
-
-
78649325858
-
Target-specific delivery of peptide-based probes for PET imaging
-
Chen K., Conti P.S. Target-specific delivery of peptide-based probes for PET imaging. Adv Drug Deliv Rev 2010, 62:1005-1022.
-
(2010)
Adv Drug Deliv Rev
, vol.62
, pp. 1005-1022
-
-
Chen, K.1
Conti, P.S.2
-
56
-
-
0038064430
-
Octreoscan radioreceptor imaging
-
van der Lely A.J., de Herder W.W., Krenning E.P., Kwekkeboom D.J. Octreoscan radioreceptor imaging. Endocrine 2003, 20:307-311.
-
(2003)
Endocrine
, vol.20
, pp. 307-311
-
-
van der Lely, A.J.1
de Herder, W.W.2
Krenning, E.P.3
Kwekkeboom, D.J.4
-
57
-
-
84877131430
-
Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin
-
Dumont R.A., Tamma M., Braun F., Borkowski S., Reubi J.C., Maecke H., et al. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin. J Nucl Med 2013, 54:762-769.
-
(2013)
J Nucl Med
, vol.54
, pp. 762-769
-
-
Dumont, R.A.1
Tamma, M.2
Braun, F.3
Borkowski, S.4
Reubi, J.C.5
Maecke, H.6
-
58
-
-
0035988207
-
Pm-149 DOTA bombesin analogs for potential radiotherapy. in vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-betaAla-BBN(7-14)NH(2)
-
Hu F., Cutler C.S., Hoffman T., Sieckman G., Volkert W.A., Jurisson S.S. Pm-149 DOTA bombesin analogs for potential radiotherapy. in vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-betaAla-BBN(7-14)NH(2). Nucl Med Biol 2002, 29:423-430.
-
(2002)
Nucl Med Biol
, vol.29
, pp. 423-430
-
-
Hu, F.1
Cutler, C.S.2
Hoffman, T.3
Sieckman, G.4
Volkert, W.A.5
Jurisson, S.S.6
-
59
-
-
33744812175
-
Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice
-
Johnson C.V., Shelton T., Smith C.J., Ma L., Perry M.C., Volkert W.A., et al. Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. Cancer Biother Radiopharm 2006, 21:155-166.
-
(2006)
Cancer Biother Radiopharm
, vol.21
, pp. 155-166
-
-
Johnson, C.V.1
Shelton, T.2
Smith, C.J.3
Ma, L.4
Perry, M.C.5
Volkert, W.A.6
-
61
-
-
0037291708
-
177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells
-
177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. Nucl Med Biol 2003, 30:101-109.
-
(2003)
Nucl Med Biol
, vol.30
, pp. 101-109
-
-
Smith, C.J.1
Gali, H.2
Sieckman, G.L.3
Hayes, D.L.4
Owen, N.K.5
Mazuru, D.G.6
-
62
-
-
4644360336
-
Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors
-
Zhang H., Chen J., Waldherr C., Hinni K., Waser B., Reubi J.C., et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 2004, 64:6707-6715.
-
(2004)
Cancer Res
, vol.64
, pp. 6707-6715
-
-
Zhang, H.1
Chen, J.2
Waldherr, C.3
Hinni, K.4
Waser, B.5
Reubi, J.C.6
-
65
-
-
34548119893
-
DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours
-
Zhang H., Schuhmacher J., Waser B., Wild D., Eisenhut M., Reubi J.C., et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging 2007, 34:1198-1208.
-
(2007)
Eur J Nucl Med Mol Imaging
, vol.34
, pp. 1198-1208
-
-
Zhang, H.1
Schuhmacher, J.2
Waser, B.3
Wild, D.4
Eisenhut, M.5
Reubi, J.C.6
-
68
-
-
0034184839
-
Labeling and in vivo evaluation of novel copper(II) dioxotetraazamacrocyclic complexes
-
Cutler C.S., Wuest M., Anderson C.J., Reichert D.E., Sun Y., Martell A.E., et al. Labeling and in vivo evaluation of novel copper(II) dioxotetraazamacrocyclic complexes. Nucl Med Biol 2000, 27:375-380.
-
(2000)
Nucl Med Biol
, vol.27
, pp. 375-380
-
-
Cutler, C.S.1
Wuest, M.2
Anderson, C.J.3
Reichert, D.E.4
Sun, Y.5
Martell, A.E.6
-
69
-
-
0034518370
-
Current and potential therapeutic uses of lanthanide radioisotopes
-
Cutler C.S., Smith C.J., Ehrhardt G.J., Tyler T.T., Jurisson S.S., Deutsch E. Current and potential therapeutic uses of lanthanide radioisotopes. Cancer Biother Radiopharm 2000, 15:531-545.
-
(2000)
Cancer Biother Radiopharm
, vol.15
, pp. 531-545
-
-
Cutler, C.S.1
Smith, C.J.2
Ehrhardt, G.J.3
Tyler, T.T.4
Jurisson, S.S.5
Deutsch, E.6
-
70
-
-
79551537113
-
Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours
-
Mansi R., Wang X., Forrer F., Waser B., Cescato R., Graham K., et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 2011, 38:97-107.
-
(2011)
Eur J Nucl Med Mol Imaging
, vol.38
, pp. 97-107
-
-
Mansi, R.1
Wang, X.2
Forrer, F.3
Waser, B.4
Cescato, R.5
Graham, K.6
-
71
-
-
0026334978
-
Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells
-
Gladson C.L., Cheresh D.A. Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest 1991, 88:1924-1932.
-
(1991)
J Clin Invest
, vol.88
, pp. 1924-1932
-
-
Gladson, C.L.1
Cheresh, D.A.2
-
73
-
-
38949198118
-
Bombesin receptor antagonists may be preferable to agonists for tumor targeting
-
Cescato R., Maina T., Nock B., Nikolopoulou A., Charalambidis D., Piccand V., et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008, 49:318-326.
-
(2008)
J Nucl Med
, vol.49
, pp. 318-326
-
-
Cescato, R.1
Maina, T.2
Nock, B.3
Nikolopoulou, A.4
Charalambidis, D.5
Piccand, V.6
-
74
-
-
33750823665
-
Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors
-
Ginj M., Zhang H., Waser B., Cescato R., Wild D., Wang X., et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A 2006, 103:16436-16441.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 16436-16441
-
-
Ginj, M.1
Zhang, H.2
Waser, B.3
Cescato, R.4
Wild, D.5
Wang, X.6
|